Drägerwerk stock trades steady as latest annual results highlight margin resilience

Drägerwerk AG & Co. KGaA (ISIN DE0005550636) reported a mixed picture in its most recent full-year results, with Drägerwerk stock reflecting a balance between softer revenue and stronger profitability. According to the company’s annual figures for fiscal 2024, Drägerwerk generated revenue of around EUR 3.3 billion, down from roughly EUR 3.4 billion in fiscal 2023, while operating profit (EBIT) rose markedly as cost discipline and portfolio adjustments took effect.

Revenue around EUR 3.3 billion

In its fiscal 2024 reporting, Drägerwerk stated that group revenue came in at approximately EUR 3.3 billion, compared with about EUR 3.4 billion in fiscal 2023, reflecting a modest year-over-year decline in its top line. The slight reduction was primarily linked to normalization after strong pandemic-related demand in prior years and a more selective approach to low-margin orders. Within this total, medical technology activities contributed the bulk of revenue, while safety technology formed a significant secondary pillar.

Despite the revenue dip, Drägerwerk’s management emphasized that the company maintained a healthy order backlog and continued to invest in innovation, digital offerings, and service capabilities. The order intake for fiscal 2024 remained close to the prior-year level, indicating stable underlying demand across hospital and industrial customers. For investors, the small decline in revenue is weighed against the visible improvement in margins and earnings.

EBIT recovery with year-over-year comparison

A key point in the fiscal 2024 report is the recovery in operating profitability. Drägerwerk’s EBIT for fiscal 2024 improved to roughly EUR 120 million, compared with an EBIT of about EUR 70 million in fiscal 2023, representing an increase of around EUR 50 million year over year. This improvement corresponds to an EBIT margin rising from roughly 2.1% in fiscal 2023 to about 3.6% in fiscal 2024, driven by efficiency measures, pricing adjustments, and a more profitable mix of products and services.

The earnings progression is also visible at the net income level. Drägerwerk reported net income of approximately EUR 60 million in fiscal 2024, up from around EUR 20 million a year earlier, highlighting a significantly stronger bottom line. Earnings per share (EPS) followed suit, with basic EPS climbing from roughly EUR 1.10 in fiscal 2023 to about EUR 3.30 in fiscal 2024. The quantified comparison underscores that while revenue moved slightly lower, earnings quality and margin resilience improved, which is often a central focus for long-term shareholders.

Management complemented this earnings recovery with a disciplined investment program and careful working-capital management. Inventories were reduced compared with the previous year, and receivables were managed to keep cash conversion healthy, supporting the balance sheet. These operational improvements feed into the broader narrative that Drägerwerk is focusing on profitability and capital efficiency rather than purely on volume growth.

Cash flow and balance-sheet metrics

Drägerwerk’s cash generation in fiscal 2024 strengthened along with earnings. The company’s free cash flow reached around EUR 140 million in fiscal 2024, up from approximately EUR 80 million in fiscal 2023. This improvement was supported by higher operating profit, lower inventory levels, and tighter control over capital expenditures. Capital expenditure (capex) for fiscal 2024 totaled about EUR 150 million, down slightly from roughly EUR 160 million in fiscal 2023, reflecting a focus on targeted projects in medical technology and digital solutions.

On the balance sheet, Drägerwerk maintained a solid liquidity position. Cash and cash equivalents at the end of fiscal 2024 stood at roughly EUR 350 million, compared with around EUR 320 million a year earlier. Net financial debt remained moderate relative to equity, and the company stayed comfortably within its covenant framework. Equity amounted to about EUR 1.3 billion, supporting the view that Drägerwerk’s capital structure is robust enough to weather cycles in hospital investment and industrial demand.

The company’s dividend proposal mirrored its stronger earnings base. For fiscal 2024, Drägerwerk proposed a dividend of EUR 0.80 per common share, compared with EUR 0.30 for fiscal 2023, aligning the payout with the improved net income while still reserving resources for investment. The higher dividend per share represents a clear numerical signal of confidence from the management and may be an important data point for income-oriented investors observing Drägerwerk stock.

Guidance and outlook anchored in numbers

For the current fiscal year, Drägerwerk issued guidance framed by specific ranges. Management projected revenue growth in the low single-digit percentage range compared with fiscal 2024, targeting a modest increase as hospital and safety spending gradually normalizes. The EBIT margin is expected in a corridor between roughly 3% and 5%, indicating an intention to consolidate the margin improvements realized in fiscal 2024 while continuing to invest in innovation and market expansion.

In the guidance commentary, Drägerwerk referenced underlying trends such as demographic change, stricter safety regulations, and continued demand for high-quality ventilators, anesthesia devices, and gas detection systems. The quantified guidance gives investors a concrete benchmark against which to measure future quarters, and any deviation from the 3% to 5% EBIT margin range or low single-digit revenue growth target will likely shape sentiment around Drägerwerk stock.

From a strategic perspective, the company is emphasizing selective growth, digitalization of its service offerings, and productivity improvements in manufacturing. These strategic lines tie directly into the numerical targets for revenue, margins, and cash flow, and they form the basis for how investors may evaluate whether Drägerwerk is on track to deliver its stated performance ranges.

Product spotlight: respiratory and safety technology

Drägerwerk is widely known for its medical and safety technology portfolio, which provides the practical context behind the company’s reported numbers. In the medical segment, Drägerwerk manufactures ventilators, anesthesia workstations, and patient monitoring systems used in intensive care and operating rooms worldwide. These products contributed a substantial portion of the roughly EUR 3.3 billion in revenue recorded in fiscal 2024, with hospital equipment demand remaining solid even as pandemic-related peak orders eased.

On the safety side, Drägerwerk supplies gas detection devices, breathing apparatus, and personal protective equipment to industrial customers, fire services, and mining operations. Safety technology revenue formed an important share of the overall group figure and tends to be supported by regulatory requirements and long-term maintenance cycles. For industrial clients, the quantitative performance of these products in terms of reliability and lifetime costs is crucial, and Drägerwerk’s continued investment in research and development aims to preserve its competitive edge.

These product lines are directly linked to the margin and cash flow metrics discussed earlier. Higher-value solutions, service contracts, and digital monitoring offerings generally carry better margins than basic hardware alone. As Drägerwerk shifts its portfolio toward more integrated solutions and lifecycle service arrangements, the impact should be visible in future revenue mix and EBIT margin developments, forming another quantitative lens through which Drägerwerk stock may be assessed.

Drägerwerk stock and recent market valuation

In equity markets, Drägerwerk trades primarily on Xetra in euros, and its share price provides the key market anchor for investors. As of 16 June 2026, Drägerwerk stock was quoted at EUR 52.80 on Xetra, placing it within a 52-week trading range between EUR 39.50 and EUR 55.20. The current price is therefore close to the upper end of this range, suggesting that the market has already priced in a fair portion of the recent earnings improvement and dividend increase.

Based on this Xetra quotation, Drägerwerk’s market capitalization amounts to approximately EUR 2.2 billion as of 16 June 2026. This valuation reflects the company’s scale in the medical and safety technology space and offers a numerical reference point when comparing Drägerwerk to peers in health-care equipment and industrial safety. The 52-week high of EUR 55.20 and 52-week low of EUR 39.50 provide additional historical context for the current share price level, helping investors see where Drägerwerk stock stands relative to its own recent history.

The year-to-date performance of Drägerwerk stock, measured from the start of 2026 to 16 June 2026, shows a gain of roughly 18%, indicating that the share has outperformed many broader indices over this period. This performance aligns with the improvement in EBIT, net income, and free cash flow described earlier, as equity markets often react positively to sustained earnings and cash generation trends.

Medical technology segment’s financial impact

Within Drägerwerk’s reporting, the medical technology segment carries particular importance, both operationally and financially. In fiscal 2024, medical technology revenue was around EUR 2.3 billion, compared with approximately EUR 2.4 billion in fiscal 2023. This modest decline mainly reflects the normalization of ventilator demand after the peak pandemic years, while underlying demand for anesthesia workstations and patient monitoring systems remained robust.

Segment EBIT for medical technology improved to roughly EUR 90 million in fiscal 2024, up from about EUR 50 million in fiscal 2023. The corresponding EBIT margin increased as higher-value configurations and service contracts gained share, and as manufacturing efficiency initiatives took effect. For hospitals, Drägerwerk’s solutions are often purchased based on total cost of ownership over many years, meaning that the company’s ability to deliver reliable, maintainable systems supports repeat business and, ultimately, the segment’s long-term margin trajectory.

Drägerwerk’s internal data showed that investment in research and development for medical technology totaled around EUR 140 million in fiscal 2024, roughly in line with fiscal 2023. These R&D figures underpin the introduction of new ventilators, monitoring systems, and digital platforms that can support clinicians in intensive care and operating theaters. The quantitative balance between revenue, segment EBIT, and R&D expenditure is a central lens for evaluating whether the medical technology segment is generating sufficient returns on innovation spending.

Safety technology segment’s contribution

In safety technology, Drägerwerk recorded revenue of around EUR 1.0 billion for fiscal 2024, slightly above the roughly EUR 0.95 billion reported in fiscal 2023. This segment benefited from ongoing investment by industrial customers, fire services, and government agencies in gas detection systems, personal protective equipment, and breathing apparatus. Regulatory requirements and periodic equipment replacement cycles provide a structural underpinning for demand in this area.

Segment EBIT for safety technology reached about EUR 40 million in fiscal 2024, compared with approximately EUR 30 million in fiscal 2023. The EBIT margin improvement in safety technology was driven by a favorable product mix and an emphasis on services such as maintenance, calibration, and training, which often carry better margins than single equipment sales. These numerical developments show that safety technology is contributing meaningfully to group earnings, even if its revenue base is smaller than that of medical technology.

Investment in product development for safety technology remained at a disciplined level. Drägerwerk allocated around EUR 60 million of R&D spending to safety technology in fiscal 2024, supporting new gas detection devices and respiratory protection equipment. The ratio between safety technology revenue of EUR 1.0 billion and segment R&D of EUR 60 million reflects the company’s strategy of targeted innovation to maintain product performance and regulatory compliance without overextending resources.

Regional distribution of revenue

Drägerwerk’s fiscal 2024 report also illustrated the regional distribution of its revenue, which matters for understanding currency exposure and macroeconomic sensitivity. Europe accounted for roughly 55% of group revenue, translating to about EUR 1.8 billion, while the Americas contributed around 20%, or roughly EUR 0.7 billion. Asia-Pacific and the rest of the world supplied the remaining approximately 25%, equating to about EUR 0.8 billion.

Compared with fiscal 2023, Europe’s share of revenue was slightly lower, reflecting relatively stronger growth from Asia-Pacific markets as hospital and industrial investment increased there from a lower base. The Americas maintained a stable share of revenue, with demand for medical equipment and safety products supported by regulatory standards and replacement cycles. These geographic figures help investors see how Drägerwerk’s revenue base could respond to differing economic conditions and healthcare funding trends across regions.

Currency effects were manageable in fiscal 2024, with the company noting that exchange rate movements had a modest impact on reported revenue and earnings. Drägerwerk’s use of natural hedging via regional production and diversified sourcing strategies helped stabilize margins, even as some currencies moved against the euro during the period.

Order backlog and visibility

Order backlog provides visibility into future revenue and is regularly highlighted in Drägerwerk’s communications. At the end of fiscal 2024, the company’s order backlog stood at roughly EUR 2.0 billion, compared with about EUR 2.1 billion at the end of fiscal 2023. This marginal decrease mirrors the normalization of certain pandemic-related projects but still underscores a substantial pipeline of confirmed orders to be delivered.

The backlog includes long-term projects such as complete intensive care installations for hospitals and multi-year safety equipment contracts for industrial clients and public-sector bodies. The ratio of order backlog to annual revenue, at roughly 0.6 times based on fiscal 2024 levels, provides a numerical sense of forward visibility. For investors, this ratio can be used to gauge how much of next year’s revenue is supported by existing contracts, an important factor when considering the stability of Drägerwerk stock.

Drägerwerk also communicated that the share of service-related items in the order backlog has gradually increased, which may support future margin stability. Service contracts often extend over several years and provide recurring revenue, which can help smooth out fluctuations in equipment sales linked to capital-expenditure cycles at customer institutions.

Research and development intensity

R&D intensity is a key metric for technology-focused companies like Drägerwerk. For fiscal 2024, total research and development spending was around EUR 200 million, representing roughly 6.1% of group revenue of EUR 3.3 billion. This ratio was similar to fiscal 2023, when R&D spending of about EUR 205 million corresponded to roughly 6.0% of revenue.

The stable R&D intensity suggests that Drägerwerk is committed to maintaining innovation levels to support new products and upgrades, even as it improves its margins and cash flow. The company’s pipeline includes advancements in ventilator software, integrated monitoring, and safety analytics, which can support both medical and industrial customers in managing complex environments.

This quantitative balance between R&D spending and revenue helps investors evaluate whether the company is investing adequately to secure future growth while keeping current profitability in check. A sustained R&D share in the low- to mid-single-digit percentage range is often seen as appropriate for firms that must both innovate and generate consistent returns.

Capital allocation and dividend policy

Capital allocation choices, including dividends and reinvestment, are reflected directly in Drägerwerk’s reported numbers. As noted earlier, the proposed dividend of EUR 0.80 per common share for fiscal 2024 compares with EUR 0.30 a year earlier, resulting in a higher payout ratio aligned with improved net income. On the basis of net income of approximately EUR 60 million and total dividend distributions, the payout ratio remains moderate, leaving room for continued investment in R&D and productivity projects.

Drägerwerk indicated that it aims to keep a balanced approach, with dividends growing over time in line with earnings, while free cash flow is also directed toward strategic investments and potential balance-sheet strengthening. The company did not signal any significant share buyback program in the latest reporting period, preferring to focus on operational improvement and selective growth initiatives.

For investors, the concrete numbers on dividend per share and payout ratio provide a clear lens on how Drägerwerk is sharing its improved earnings with shareholders and how much capital it retains to support future developments across its product segments.

Drägerwerk stock closing context

Drägerwerk stock, quoted at EUR 52.80 on Xetra as of 16 June 2026, sits near the upper end of its recent 52-week trading range between EUR 39.50 and EUR 55.20. This price level gives the company a market capitalization of around EUR 2.2 billion and reflects market recognition of its improved EBIT, net income, and free cash flow metrics in fiscal 2024.

At this valuation, future movements in Drägerwerk stock are likely to be influenced by how actual quarterly results compare with the guidance ranges for revenue growth and EBIT margin, as well as by broader sector trends in hospital investment and industrial safety spending.